EZZ is in a solid financial position to build on its growth strategy after a strong Q3 FY22 which has seen the company close the quarter with ~$10.4 million in cash. Genomic-tech firm, EZZ Life Science Holdings (ASX:EZZ) has closed a successful Q3 FY22 with ~$4 million in cash inflows from customers as it gradually …
Read more “EZZ Posts ~$4 Million Cash Inflows in Q3 as Covid-19 Recovery Continues”
Shared from the 3/31/2022 Financial Review eEdition Life sciences is one of the fastest growing industries in the world, with companies investing heavily in scientific research for the betterment of humankind. The industry comprises companies operating across a broad spectrum; engaging in the research, development and manufacturing of pharmaceuticals, biotechnology-based food and medicines, medical devices, …
By George Tchetvertakov There is a palatable global trend towards greater health consciousness and it’s accelerating, Australian life science company EZZ Life Science (ASX: EZZ) told attendees at its gastrointestinal health conference last week. With the COVID-19 pandemic now ebbing away, albeit gradually, it’s not just Australians that have learned a valuable lesson in health. …
Read more “EZZ Life Science hosts gastrointestinal health conference in Sydney”
EZZ has achieved a significant milestone after being reclassified on the ASX as the genome-specialist looks to broaden its market share in the biotech and life sciences sector. Aussie-listed genomic-tech firm, EZZ Life Science Holdings (ASX:EZZ) has had its listing changed on the bourse from retail to a pharmaceutical, biotechnology and life sciences company. The …
Read more “Transformative: EZZ achieves milestone biotech and life sciences listing on ASX”
Speakers including Luis Vitetta, Clinical Prof. with @Sydney_Uni, Gemma Acton, Network Finance Manager @7NewsSydney and Glenn Cross, EZZ Life Science Chairman.
Director of Corporate Affairs, EZZ Life Science Holdings
James Hudson is the Director of Corporate Affairs at EZZ Life Science, where he oversees media relations, investor relations, and public affairs for the company.
Before joining EZZ, James was the Director of Corporate Affairs and Marketing at Alibaba Group for Australia and New Zealand. He has also served as the CEO of the Australia China Business Council's NSW branch, where he supported member companies in trade, investment, and business engagements with China. Additionally, he has held the role of China and East Asia Adviser at CSIRO, Australia’s national science research agency.
James has been appointed to various Advisory Board and Ambassador positions, including with the Asia Education Foundation, the China Australia Millennial Project, AsiaRecon, the Asian Football Cup, and Austrade’s Approved Destination Status Advisory Panel. He has also served as a non-executive director for organisations such as OneSky Australia and the Castlemaine State Festival.
Company Secretary
Jay Stephenson has been involved in business development for over 35 years including approximately 29 years as Director, Chief Financial Officer and Company Secretary for various listed and unlisted entities in resources, manufacturing, information technology, health care, wine, hotels and property. Jay has been involved in business acquisitions, mergers, initial public offerings, capital raisings, business restructuring as well managing all areas of finance for companies.
Jay provides services in IPO/RTO management, Corporate Advisory, Company Administration, Accounting and Corporate Governance. On most engagements, Jay takes on the appointment of a statutory office holder, either as a Director, Company Secretary or Chief Financial Officer.
Jay holds a Master of Business Administration, is a Chartered Accountant, Fellow of Certified Practicing Accountants Australia, A Fellow of the Governance Institute of Australia, a member of Chartered Professional Accountants and Certified Management Accountants in Canada.
Chief Financial Officer
With over 30 years of experience as a chartered accountant, Anthony Guarna has held positions at Deloitte, BDO, and Nexia, both domestically and internationally. He has provided financial leadership at organizations such as Energy Australia, the University of Sydney, Macquarie University, Tower Life, Electroboard Group, the Australian Institute of Higher Education, Austral Gold Limited (ASX: AGD), Aumake Limited (ASX: AUK), and Freedom Insurance Group Limited (ASX: FIG). Anthony also serves as a Non-Executive Director of the Sydney Institute of Traditional Chinese Medicine and is a member of the Advisory Board at Medigalaxy.
Independent Non-Executive Director
With more than 20 years in senior management within the banking industry, Lily Huang serves as Vice President in the investment partnerships division at Citi Group Australia. Her leadership was recognized in 2015 when she was named among the Top 10 Australian Chinese Entrepreneurs.
Independent Non-Executive Director
Bringing over 30 years of legal practice experience both in Australia and internationally, Ivan Oshry specializes in corporate law. He has advised on numerous IPO transactions globally and is a sought-after speaker at various conferences, reflecting his deep industry knowledge.
Executive Director and Chief Executive Officer
An award-winning research analyst and accomplished entrepreneur, Mark Qin co-founded CE International, a multi-award-winning marketing consulting firm. Between 2003 and 2008, he authored five books on sales and marketing within the healthcare industry, showcasing his dedication to advancing the sector.
Independent Non-Executive Director and Chairman
With four decades in the life sciences sector, Glenn Cross has held senior executive roles across multinational and Australian companies. His expertise spans general management, sales, marketing, finance, distribution, and manufacturing. Notably, Glenn served as Chief Operating Officer and CEO of AusBiotech for over 13 years. Currently, he contributes as a non-executive director to various private and public companies, as well as investment funds.